Gain Therapeutics, Inc.

GANX Healthcare Biotechnology

Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.

1.26 0.07 −5.26%
Market cap
$58.1M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
1/9
Altman Z
−1.79
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(261.72%) (155.66%) (214.69%) (268.30%)
ROA
(153.07%) (115.40%) (139.91%) (159.22%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(301.48%) (106.34%) (147.61%) (173.59%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.49) (0.56) (0.46) (0.44)
Free Cash Flow
(17.30) (18.47) (19.37) (18.95)
Other line items
Cash ROIC
(114.27%) (46.39%) (62.65%) (76.67%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.07 0.04 0.05 0.05
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Operating CF/Net income
0.89 0.92 0.91 0.94
Depreciation/Fixed assets
1.02 1.26 1.74 2.12
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.49) (0.56) (0.46) (0.44)
Capex per Share
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates